Deambulatory Epidural During the Labour

May 30, 2018 updated by: Dr Madeleine Wilwerth

Comparison of Two Different Peridural During the Labor and Effect of Deambulation

Assess the impact of instrumentation and caesarean related to dyskinesia by reducing the concentration of local anesthetic and therefore the motor block.

Study Overview

Detailed Description

Prospective, randomized and double-blind study performed on primiparous parturient divided into two distinct groups.

Study Type

Interventional

Enrollment (Actual)

164

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bruxelles, Belgium, 1020
        • CHUB

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Free written consent.
  • ASA I or II,
  • Primipara, unique and pregnancy over 36 weeks fetus in cephalic, cervical dilation between 3-6 cm
  • VAS> 30 mm
  • No contraindications to peridural

Exclusion Criteria:

  • Twin pregnancy, less than 36 weeks and 42 weeks
  • Fetus in breech position
  • Analgesia and sedation within 6h
  • Contraindications to peridural

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group
Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.1% + Sufentanil 0.2 µg/mL
Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
Other Names:
  • control group
Introduction of a catheter in lumbar epidural space
Other Names:
  • labor analgesia
Experimental: Ambulatory group
Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.07% + Sufentanil 0.3 µg/mL
Introduction of a catheter in lumbar epidural space
Other Names:
  • labor analgesia
Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
Other Names:
  • ambulatory group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time between peridural application and childbirth
Time Frame: at delivery
This will be used to assess labor.
at delivery
Caesarian
Time Frame: at delivery
This will be used to assess labor. Was a caesarian necessary (yes-no) ?
at delivery
Instrumentalisation
Time Frame: at delivery
This will be used to assess labor. Was an instrumentalisation (defined as the use of forceps or suction cups) necessary at delivery (yes-no) ?
at delivery
Apgar score of the baby
Time Frame: at delivery
Evaluation of the baby, using the Apgar score. This will be used to assess labor.
at delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bromage score
Time Frame: 1h after the start of the peridural
Modified Bromage score (Breen et al) >5 and ability to stand on one leg alternatively. This will be used to assess perambulation (motricity).
1h after the start of the peridural
Romberg test
Time Frame: 1h after the start of the peridural
Romberg test during 20-30 seconds. This will be used to assess perambulation (proprioception).
1h after the start of the peridural
Arterial tension
Time Frame: 1h after the start of the peridural
Absence of orthostatic hypotension (i-e less than 20% of the usual arterial tension of the patient).
1h after the start of the peridural

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Philippe Vanderlinden, CHUB

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2014

Primary Completion (Actual)

March 20, 2018

Study Completion (Actual)

March 20, 2018

Study Registration Dates

First Submitted

August 1, 2014

First Submitted That Met QC Criteria

October 10, 2014

First Posted (Estimate)

October 15, 2014

Study Record Updates

Last Update Posted (Actual)

May 31, 2018

Last Update Submitted That Met QC Criteria

May 30, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on First Pregnancy

Clinical Trials on Levobupivacaine 0.1% + Sufentanil 0.2µg/ml

3
Subscribe